Kenneth Galbraith - Jan 15, 2022 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Role
Chair, President & CEO, Director
Signature
/s/ Daniel Dex, Attorney-in-Fact
Stock symbol
ZYME
Transactions as of
Jan 15, 2022
Transactions value $
$0
Form type
4
Date filed
1/18/2022, 05:25 AM
Previous filing
May 17, 2021
Next filing
Dec 23, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Stock Option (Right to Buy) Award $0 +500K $0.00 500K Jan 15, 2022 Common Shares 500K $14.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.